Addex Therapeutics Ltd. announced that it has terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow recruitment of patients. This has been attributed to the consequences of COVID-19 related patient concerns about participation in clinical studies as well as staffing shortages and turnover within study sites.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1155 CHF | +0.43% | -23.26% | +151.09% |
Apr. 24 | Top Premarket Decliners | MT |
Apr. 18 | Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+151.09% | 16.19M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ADXN Stock
- News Addex Therapeutics Ltd
- Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson's Disease due to Slow Recruitment Rate